[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335578-105":59,"doc-detail-335578-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nanomaterials-breaking-the-bottleneck-of-breast-cancer-drug-resistance","Nanomaterials: breaking the bottleneck of breast cancer drug resistance","","Drug resistance remains a major obstacle in breast cancer treatment. This review surveys recent advances in nanomaterials designed to selectively target tumor cells and support breast cancer therapy development. By leveraging properties such as low toxicity, strong biocompatibility, controllable preparation, antitumor drug loading, and modifiable surface functions, nanomaterials are positioned to counter multiple resistance pathways. The article discusses mechanisms of resistance improvement, targeted nanotherapy strategies, and key research progress.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanomaterials-breaking-the-bottleneck-of-breast-cancer-drug-resistance/335578/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanomaterials-breaking-the-bottleneck-of-breast-cancer-drug-resistance/335578.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is drug resistance a critical challenge in breast cancer treatment?","Question",{"text":112,"@type":113},"Drug resistance reduces the effectiveness of standard therapies such as chemotherapy by enabling cancer cells to survive and adapt. It contributes to poorer outcomes and limits long-term control of the disease.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the main cellular and molecular mechanisms of breast cancer drug resistance described in the review?",{"text":117,"@type":113},"The review highlights drug efflux and drug inactivation, enhanced DNA damage repair, activation of bypass or pro-survival pathways, epithelial-mesenchymal transition (EMT), and stem-like properties that support survival and recurrence.",{"name":119,"@type":110,"acceptedAnswer":120},"How do nanomaterials help mitigate breast cancer drug resistance?",{"text":121,"@type":113},"Nanomaterials can selectively target tumor cells and improve delivery of antitumor agents. Their properties can control drug release and localization, influencing resistance mechanisms and supporting more effective targeted therapy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335578,1790584812,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","TYPE Review  \nPUBLISHED 13 November 2024 DOI 10.3389/fimmu.2024.1492546  \nOPEN ACCESS  \nEDITED BY  \nTeruyoshi Sasayama, Kyushu University, Japan  \nREVIEWED BY  \nNian-Qiu Shi,  \nJilin Medical University, China Wentao Liu,  \nChinese Academy of Sciences (CAS), China  \n*CORRESPONDENCE  \nKeyan Chen  \n [kychen@cmu.edu.cn](kychen@cmu.edu.cn)[ ](kychen@cmu.edu.cn)Wanwei Dong  \n[wwdong@cmu.edu.cn](wwdong@cmu.edu.cn)[ ](wwdong@cmu.edu.cn)Di Zhang  \n [dzhang87@cmu.edu.cn](dzhang87@cmu.edu.cn)  \nRECEIVED 07 September 2024  \nACCEPTED 28 October 2024  \nPUBLISHED 13 November 2024  \nCITATION  \nGuan C, Han Y, Ling Z, Meng X, Zhang B, Dong W, Zhang D and Chen K (2024)  \nNanomaterials: breaking the bottleneck of breast cancer drug resistance.  \nFront. Immunol. 15:1492546 .  \ndoi: 10.3389/fimmu.2024.1492546  \nCOPYRIGHT  \n© 2024 Guan, Han, Ling, Meng, Zhang, Dong, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nNanomaterials: breaking the bottleneck of breast cancer drug resistance  \nChao Guan 1, Yahao Han 2, Zhenzheng Ling 1, Xiang Meng 1, Baolin Zhang 3, Wanwei Dong 2*, Di Zhang 4* and Keyan Chen 2*  \n1The First Clinical College of China Medical University, Shenyang, Liaoning, China, 2 Laboratory Animal Science of China Medical University, Shenyang, Liaoning, China, 3The Fourth Clinical College of China Medical University, Shenyang, Liaoning, China, 4 Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China  \nDrug resistance poses a signiﬁcant challenge in the treatment of breast cancer. In recent years, a variety of nanomaterials have been discovered and synthesized that can selectively target tumor cells and play a crucial role in the advancement of breast cancer therapies. As our understanding of tumor heterogeneity deepens, the emerging potential of nanomaterials in addressing drug resistance has garnered considerable attention. These materials not only selectively target tumor cells but also possess unique properties that make them promising options for cancer treatment, including low toxicity, excellent biocompatibility, ease of preparation, the ability to carry antitumor drugs, and customizable surface functions. In this review, we will comprehensively summarize two key developments in breast cancer treatment: the application of antitumor drugs and nanomaterials. We will explore the mechanisms by which nanomaterials improve drug resistance in breast cancer, targeted nanotherapy strategies to mitigate this resistance, and recent research advancements in anticancer nanomaterials. This overview aims to highlight the signiﬁcant role of nanomaterials in breast cancer treatment and provide a theoretical framework for identifying optimal treatment strategies in the future.  \nKEYWORDS  \nbreast cancer, nanomaterials, anticancer drugs, drug resistance, targeted therapy  \n1 Introduction  \nBreast cancer has the highest mortality rate among female cancers in many countries and regions, surpassing lung cancer to become the most commonly diagnosed cancer (1–3) . According to the American Cancer Society (1), there will be approximately 300,590 new cases of breast cancer in 2023, resulting in an estimated 43,700 deaths.  \nCurrently, the primary treatments for breast cancer include surgery, along with radiotherapy, chemotherapy, hormone therapy, and other methods (4) . Chemotherapy is a widely used approach; however, its lack of selectivity for tumor tissues presents signiﬁcant  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nchallenges (5–7) . These challenges include systemic toxicit","cbCaiuvH9KL70x1h","https://ap.wps.com/l/cbCaiuvH9KL70x1h","pdf",2915493,14,"English","# Introduction\n## Breast cancer burden and current therapies\n## Mechanisms of drug resistance\n# Nanomaterials in breast cancer treatment\n## Advantages for targeted delivery and tumor killing\n## Nanomaterials influencing resistance mechanisms\n# Targeted nanotherapy strategies\n## Addressing key resistance pathways\n# Future directions","[{\"question\":\"Why is drug resistance a critical challenge in breast cancer treatment?\",\"answer\":\"Drug resistance reduces the effectiveness of standard therapies such as chemotherapy by enabling cancer cells to survive and adapt. It contributes to poorer outcomes and limits long-term control of the disease.\"},{\"question\":\"What are the main cellular and molecular mechanisms of breast cancer drug resistance described in the review?\",\"answer\":\"The review highlights drug efflux and drug inactivation, enhanced DNA damage repair, activation of bypass or pro-survival pathways, epithelial-mesenchymal transition (EMT), and stem-like properties that support survival and recurrence.\"},{\"question\":\"How do nanomaterials help mitigate breast cancer drug resistance?\",\"answer\":\"Nanomaterials can selectively target tumor cells and improve delivery of antitumor agents. Their properties can control drug release and localization, influencing resistance mechanisms and supporting more effective targeted therapy.\"}]","Nanomaterials: breaking the bottleneck of breast cancer drug resistance | PDF",1790011491,35]